iRhythm faces investor investigation after Q3 miss; FDA submission for Zio MCT delayed to 2027

iRhythm Technologies faces an investor investigation after reporting Q3 2026 revenue of $221.6 million, below analyst consensus, with Zio AT sales flat year-over-year. Management said the FDA submission for its next-generation Zio MCT device has been delayed until 2027.

Detected & updated continuously · Source: Nebula